Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers

Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers

288092

Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers

A single dose of PHA121 (PHA-022121), Pharvaris’ investigational therapy for hereditary angioedema (HAE), is safe and can rapidly and sustainably block bradykinin-induced changes in blood parameters, according to two studies in healthy volunteers. According to the company, these findings indicate PHA121 may be well suited for use as a single oral treatment to prevent acute HAE attacks in people with the chronic swelling disorder. The results also support the launch of future clinical trials exploring…

You must be logged in to read/download the full post.